Legend Biotech is a commercial-stage cell-therapy company built around one product: CARVYKTI, a BCMA CAR-T for multiple myeloma partnered with Johnson & Johnson. The economics are shared, with costs and profits split equally outside Greater China while Legend bears and retains 70% in Greater China. Legend books its share as collaboration revenue, which reached $944.8 million in 2025 and helped push total revenue past $1.0 billion for the first time.
The franchise is still ramping fast. Quarterly CARVYKTI net trade sales climbed from roughly $439 million in Q2 2025 to $597 million in Q1 2026, up 62% year over year, with more than 10,000 patients treated by March 2026 and availability across more than 300 sites in 18 markets. The clinical story is unusually strong: five-year CARTITUDE-1 follow-up showed median overall survival of 60.7 months, with roughly one-third of patients progression-free for at least five years after a single infusion.
The catch is that volume has not yet become durable profit. Q1 2026 still showed a net loss of $54.3 million as cost of collaboration revenue jumped on capacity expansion and depreciation charges, and in June 2026 the company raised about $226 million gross by selling 7.7 million ADSs at $29.35. The report calls this a company in transition whose self-funding story remains unfinished, while competition widens from Bristol Myers Squibb's Abecma and newer BCMA bispecifics.
At $29.91 the stock sits at the bottom of the report's acceptable-hold band of $29 to $39. The rating is Hold: new capital only looks attractive at $22 to $24, and $53 and above is flagged as clearly overvalued. Expected annualized returns run 0% to 2% conservative, 5% to 8% base, and 17% to 20% optimistic, against a max-loss scenario of roughly 45% to 55%. The things to watch are margin conversion over the next few quarters and any renewed financing need.
The above is a summary of the report's views and does not constitute investment advice. Markets carry risk; invest with caution.
Prices in the article are as of publication; see the valuation band above for the live price.
Meta
- Ticker: US LEGN.US
- Company: Legend Biotech Corporation
- Price & market cap: $29.91 close as of 2026-07-02; approximately $5.8 billion equity market value using 386.9 million ordinary shares outstanding after the June 2026 follow-on offering and the 1 ADS = 2 ordinary shares ratio.
- Currency: USD
- Report date: 2026-07-03
- Industry: Biotechnology
- One-line positioning: Commercial-stage cell-therapy company whose economics are dominated by its partnered CARVYKTI franchise and its shared-profit model with Johnson & Johnson.
Research summary
Scope first. This is general-equity research, not a recommendation memo written for a specific portfolio mandate. The horizon is both the next 12 months and the next 3–5 years, with a balanced risk lens. On that basis, Legend Biotech is best understood as a single-asset commercial biotech in transition: no longer a pre-revenue science project, not yet a diversified oncology platform, and still valued mainly on whether CARVYKTI can keep outrunning the cost, capacity, and concentration risks that come with autologous cell therapy. The business the market is actually buying today is Legend’s share of CARVYKTI economics rather than “cell therapy” in the abstract, reported mainly through collaboration revenue, plus a smaller and much more speculative call option on next-generation programs such as LB2501 and LB2102. That accounting point matters. Janssen is principal in customer sales, so gross CARVYKTI trade sales do not flow into Legend’s P&L as product revenue; Legend books its pro rata share as collaboration revenue and books its share of the associated cost base in cost of collaboration revenue. In the 2025 20-F, management spelled out the economic split: Legend and Janssen share development, manufacturing, commercialization costs and profits or losses equally outside Greater China, while in Greater China Legend bears and retains 70%. Collaboration revenue of $944.8 million in 2025 therefore matters more for valuation than the franchise’s headline worldwide sales number.
The market’s current narrative has three layers. The first is the obvious one: CARVYKTI is still ramping fast. Net trade sales rose from approximately $439 million in Q2 2025 to $524 million in Q3 2025, $555 million in Q4 2025, and $597 million in Q1 2026, with Q1 up 62% year over year. More than 10,000 patients had been treated by March 2026, and management reported availability across more than 300 sites and 18 markets by May 2026. The second layer is margin conversion: investors are testing whether a business that was built around one extremely complex autologous therapy can translate volume into durable profitability rather than simply into higher manufacturing and commercialization spend. The third layer, newly added in mid-2026, is platform optionality: LB2501’s early in vivo CAR-T data created the first serious market argument that Legend might one day deserve something more than a one-franchise multiple.
That explains most of the share-price history. The first major move came at IPO in June 2020, when the ADSs were priced at $23 and opened much higher, as the market treated Legend as a high-beta, China-origin cell-therapy pure play tied to promising BCMA CAR-T science. Reuters reported a market debut opening price of $37, implying a valuation around $4.8 billion. The second move came around the 2022 U.S. approval of CARVYKTI and the shift from pure clinical promise to commercial execution. The third, and most important, re-rating phase came in 2023–2024 as the market began to price earlier-line potential against supply constraints. The stock’s historical peak closing price was reached in July 2023, then the center of gravity moved down as investors learned that demand alone does not scale a CAR-T franchise; manufacturing slots, turnaround time, treatment-center expansion, and safety-logistics infrastructure all matter. The April 2024 U.S. label expansion into patients who had received at least one prior line of therapy and were lenalidomide-refractory kept the franchise thesis alive, but the July 2026 price still sits far below the 2023 peak because the market wants proof that faster demand can become cash earnings rather than just a larger bottleneck.
The core bull-bear disagreement is therefore not about whether CARVYKTI works. The clinical and commercial evidence is too strong for that to be the main fight. CARTITUDE-1 five-year follow-up presented at ASCO 2025 showed median overall survival of 60.7 months and roughly one-third of patients progression-free for at least five years after a single infusion. The bigger argument is whether CARVYKTI becomes a very large franchise before competing modalities and manufacturing friction cap its economics. Bulls see a product with unusual efficacy, a label already expanded toward earlier lines, improving manufacturing success rates, new supply support from Novartis, and a partnership with Johnson & Johnson that gives global execution heft. Bears see a product whose economics are shared, whose delivery model remains operationally hard, whose cost base still rises with capacity, and whose competitive set is widening not only with Bristol Myers Squibb’s Abecma but with BCMA bispecifics and adjacent myeloma regimens that may chip away at the highest-value patient pools.
The best single phrase for the company today is a company in transition, not “high-quality compounding growth.” The reason is simple. Legend has already crossed a real threshold: it generated more than $1.0 billion of revenue in 2025, almost all of it tied to a marketed product, and management could credibly say the CARVYKTI franchise was profitable for full-year 2025. But it has not crossed the second threshold that matters for long-term equity owners: proving that the franchise can fund a broader pipeline without repeated dilution or a steadily rising governance discount. Q1 2026 still showed an operating loss of $49.8 million and a net loss of $54.3 million, even as CARVYKTI sales hit a new quarterly high, because cost of collaboration revenue jumped on higher cost of sales plus one-time capacity-expansion and depreciation charges. Then, in June 2026, Legend sold 7.7 million ADSs at $29.35, raising about $226 million gross. That financing does not mean the company is distressed. It does mean the self-funding story remains unfinished.
The capital-markets angle deserves extra restraint. At $29.91, the stock is not expensive in the way it looked near the 2023 peak. But it is not obviously cheap either if one uses owner economics rather than headline franchise sales. After the June 2026 offering, the balance sheet is stronger, yet existing shareholders still own a business where almost all near-term value depends on one asset, one partner, one manufacturing chain, and one disease setting. That concentration can produce spectacular upside if CARVYKTI keeps moving earlier, community access broadens, and manufacturing constraints continue to ease. It also means mistakes are not diversified away.
My bottom-line portrait, before any formal rating, is this. Legend has already proven something important: it can take a China-origin, U.S.-listed cell-therapy company from spinout to globally commercial product with one of the strongest efficacy stories in multiple myeloma. What it has not yet proven is equally important: that this success can become a stable, multi-asset, self-funded compounding machine. Until that second proof arrives, the right frame is a strong franchise with real execution quality, real platform optionality, and real concentration risk.
Company vertical history
Origins and listing path
Legend Biotech was incorporated in the Cayman Islands on May 27, 2015. The company emerged from the broader GenScript ecosystem, and its institutional DNA still shows that origin: China operating roots, Cayman holdco structure, U.S. capital-market access, and a founding shareholder that remained controlling for years. The 2025 20-F states that the company’s ultimate holding company is GenScript Corporation and details the cross-border subsidiary structure spanning the U.S., China, Ireland and Belgium. That structure was the architecture required to fund advanced cell-therapy development across jurisdictions, not a cosmetic listing choice, while preserving access to U.S. investors and multinational clinical development.
The founding problem Legend set out to solve was to turn highly customized cell engineering into a repeatable oncology platform, not simply to “make another CAR-T.” In practice, the company’s first decisive bet became BCMA-directed CAR-T in multiple myeloma. That bet mattered because myeloma already had an established therapeutic ladder, yet late-line patients still had poor outcomes and room for deep-response therapies. Legend’s 2017 worldwide collaboration with Janssen turned a promising platform company into a focused development vehicle for cilta-cel. In hindsight, that deal defined the franchise. It lowered development and commercialization risk, but it also permanently gave up half the economics outside Greater China.
Legend listed on Nasdaq in June 2020. The company announced IPO pricing at $23 per ADS; the ADSs began trading on June 5, 2020, and the offering closed on June 9, 2020. After underwriters exercised their option, the IPO totaled 21.19 million ADSs at $23, generating about $487.3 million gross, alongside a concurrent sale of ordinary shares to GenScript. At IPO, the market understood Legend as a clinical-stage CAR-T pure play with unusually high science quality, unusual geopolitical complexity, and one unusually important partnered asset. That understanding remains surprisingly durable even now.
Development stages and lasting inflections
The first stage ran from incorporation through IPO. The company was still a capital-consuming R&D organization, and the key management problem was not scale but proof: get enough clinical evidence, manufacturing capability, and financing credibility to justify public-market funding. Revenue in that era was mostly license and milestone based, not recurring commercial income. In 2020 total revenue was $75.0 million, while operating cash burn was $223.0 million. The share-price story at that stage was pure optionality. Investors paid for science, partner validation, and the scarcity value of a listed cell-therapy pure play.
The second stage began with the move from pre-approval preparation to launch. CARVYKTI received U.S. approval in February 2022 for heavily pretreated relapsed or refractory multiple myeloma, and Japan’s review documents from 2022 described the product for patients with at least three prior lines including PI, IMiD and anti-CD38 exposure. That was the turning point at which commercial organization, treatment-center onboarding, and manufacturing reliability became as important as trial data. Financials still looked ugly because Legend was spending ahead of revenue, but the nature of the spending changed. Selling and distribution expense in 2021 rose sharply as the company prepared for the U.S. launch.
The third stage was the painful but productive scale-up phase of 2023–2024. Revenue accelerated from $285.1 million in 2023 to $627.3 million in 2024 as collaboration revenue rose from $249.8 million to $482.6 million. Yet this was also the phase in which the market learned that autologous CAR-T is not a normal biotech launch. Scale required manufacturing expansion, logistics discipline, treatment-center growth, and partner coordination. Legend entered a Master Manufacturing and Supply Services Agreement with Novartis in early 2024, and management later cited initiation of commercial production at a Novartis facility and ongoing capacity expansion in Belgium and Raritan. The business started to look less like a science bet and more like a constrained industrial system.
The fourth stage is the current one: commercial validation with strategic optionality. This phase opened with the April 2024 U.S. earlier-line approval, widened through 2025 as CARVYKTI sales moved from about $157 million in Q1 2024 to $1.9 billion for full-year 2025, and changed character again in June 2026 when LB2501’s early in vivo CAR-T data triggered a new narrative around platform value. The heroic version of this stage says Legend has built the world’s best positioned pure-play cell-therapy company. The skeptical version says the market is once again paying for a second curve before the first one has fully proven bottom-line durability. Both views have evidence behind them.
Financial vertical review and price history
The reported revenue arc is clean. Total revenue rose from $75.0 million in 2020 to $68.8 million in 2021, then to $117.0 million in 2022, $285.1 million in 2023, $627.3 million in 2024, and $1,028.9 million in 2025. The engine behind that move was collaboration revenue, which went from zero in 2021 to $66.7 million in 2022, $249.8 million in 2023, $482.6 million in 2024, and $944.8 million in 2025. This is exactly what investors should have wanted to see from a partnered commercial-stage biotech: the business migrated from milestone dependence to repeatable franchise economics.
The earnings-quality story is less clean but understandable. Net loss stayed large at $(403.6) million in 2021, $(446.3) million in 2022, $(518.3) million in 2023, $(177.0) million in 2024, and $(296.8) million in 2025. The 2024 improvement and 2025 slippage do not mean the business regressed operationally. They reflect the messy reality of scaling a cell-therapy franchise under IFRS: costs move with ramp, manufacturing expansion creates depreciation and one-time items, and FX can distort net income. Operating cash flow improved materially over time, though it remained negative: operating cash outflow was $223.0 million in 2020, $198.5 million in 2021, $201.3 million in 2022, $393.3 million in 2023, $144.0 million in 2024, and $100.2 million in 2025. The 2023 bulge is the outlier; the 2024–2025 trend is the more relevant one.
The balance sheet is still a strategic asset. Cash and time deposits stood at $949 million at year-end 2025 and $834.6 million at March 31, 2026, before the June 2026 gross equity raise of about $226 million. That is enough to keep Legend out of near-term financing distress, but not enough to make dilution risk disappear if the company decides to accelerate platform spending while profitability remains only partly proven. The June 2026 deal is the clearest evidence that management still values strategic flexibility over avoiding dilution at all cost.
The ownership story shows the company gradually reducing, but not eliminating, the GenScript shadow. The 2025 20-F lists GenScript as beneficial owner of 174.5 million ordinary shares, or 47.2%, as of February 28, 2026. Using the post-offering ordinary-share count of 386.9 million and assuming GenScript did not participate, its stake would have diluted to roughly 45.1% before any underwriter option exercise. That is still a controlling-or-near-controlling block in practical terms, and it matters because Legend still has related-party transactions, lease ties, and board overlap with the GenScript ecosystem. The company is more independent than it was at IPO, but the governance discount has not vanished.
Business model, moat, industry and competition
How the business really works
Legend now has a simple income statement and a complicated operating engine. Economically, the company is dominated by one product. In 2025, collaboration revenue of $944.8 million accounted for more than 90% of total revenue, while license and other revenue contributed $84.1 million, including Novartis-related revenue and a related-party sublicense stream. That concentration will likely stay extreme for several years. It means investors should model Legend less like a diversified oncology company and more like a royalty-and-profit-share franchise with attached platform R&D.
The cost structure has both variable and sticky elements. Cost of collaboration revenue rises with sales volume, but the harder piece is the semi-fixed manufacturing and commercial infrastructure needed to support CAR-T scale. In Q1 2026, cost of collaboration revenue rose to $175.4 million from $69.5 million a year earlier, driven by higher cost of sales and one-time capacity-expansion and depreciation charges. That tells you why the margin debate remains open. Legend plainly has operating leverage if the manufacturing base is already in place and failure rates keep improving. It also plainly has negative operating leverage when new capacity, new markets, and new community infrastructure have to be built ahead of demand.
The moat is real, but narrower than the most enthusiastic narrative suggests. The first real moat is clinical differentiation. CARVYKTI’s long-term data remain unusually strong in myeloma, and its earlier-line approval created a meaningful first-mover advantage for BCMA-directed therapy in second line and beyond. The second is execution through partnership. Johnson & Johnson brings global commercial infrastructure, payer access, and physician reach that Legend would not have built alone on the same timetable. The third is manufacturing know-how. The company reported a 99% manufacturing success rate in Q1 2026, shorter turnaround times, more than 95% on-time order release, and capacity augmentation through Raritan, Belgium and Novartis support. The fourth is organizational learning: treatment-center onboarding, patient-selection workflows, and vein-to-vein coordination improve with scale and are hard for newcomers to replicate quickly.
What is not a moat is just as important. Legend does not have a diversified revenue base. It does not fully control commercialization outside Greater China. It does not have the kind of platform breadth that protects a company from one franchise setback. And it is not insulated from modality substitution. Bispecific antibodies are not “better CAR-T,” but they are easier to deliver, easier to schedule, and easier for community practices to adopt. In an adverse reimbursement or capacity environment, convenience becomes competitive. That is why the moat is best described as strong around one therapy today, but not yet broad at the corporate level.
Management, governance and geopolitical overlay
Ying Huang has been CEO since September 2020 after having served as CFO, and before that she was head of biotech equity research at BofA Securities. That background shows up in Legend’s investor communication: management generally explains the business in the language of capital allocation and margin conversion, not just science. CFO Carlos Santos joined in August 2025 from AstraZeneca’s oncology organization, reinforcing the operational-commercial bias of the current management bench.
Governance is workable, not pristine. The board is classified. Fangliang Zhang, a GenScript executive, serves as chairman and is not independent under Nasdaq rules; the company designates Peter Salovey as lead independent director because the chair is not independent. GenScript remained a 47.2% shareholder as of late February 2026. Related-party transactions remain visible, including purchases from GenScript- and ProBio-related entities totaling $14.3 million in 2025, facility and animal-service arrangements, and reciprocal service agreements. None of that proves abuse. It does mean investors should keep a standing governance discount in the valuation.
The geopolitical risk is specific, not theoretical. Legend’s 20-F includes a dedicated “holding company structure and China operations” discussion, noting PRC oversight risk, capital controls risk, tax-residency risk, and evidentiary limitations for U.S. investors. Separately, in May 2024 a bipartisan House Select Committee sought intelligence briefings on GenScript and its segments including Legend; Reuters reported renewed U.S. congressional concerns again in July 2025. Legend’s auditor is U.S.-based Ernst & Young LLP and the 20-F notes it is inspected by the PCAOB and has not been subject to an HFCAA determination, which materially reduces but does not erase listing-risk anxiety. The right conclusion is neither panic nor dismissal. The current risk is political overhang and valuation discount, not an immediate operating block.
Horizontal competitor analysis
Legend’s true competitive set is the evolving treatment sequence in relapsed multiple myeloma, not “other cell-therapy companies.” The most direct product competitor is Bristol Myers Squibb’s Abecma. BMS reported 2025 Abecma sales of $427 million, far below the scale of the CARVYKTI franchise, and Reuters noted in 2025 that Bristol was buying 2seventy bio partly to eliminate profit-sharing friction while trying to stabilize a trailing franchise. That matters because it suggests the BCMA CAR-T market is not winner-take-all, but CARVYKTI clearly entered 2026 with the stronger commercial trajectory.
The next set of competitors are BCMA bispecifics. Pfizer’s Elrexfio is commercially relevant not because it has matched CARVYKTI’s efficacy profile, but because it keeps moving earlier and is much easier to deploy. Pfizer’s Q1 2026 release highlighted positive Phase 3 MagnetisMM-5 results in patients with at least one prior line of therapy. Regeneron’s Lynozyfic received accelerated FDA approval in July 2025 after at least four prior lines. Johnson & Johnson’s own Tecvayli sits in the same substitution pool, while Talvey competes through a different target, GPRC5D, but still affects sequencing. A physician deciding between bispecifics and CAR-T is not choosing the same clinical object; they are choosing between depth of response, logistics, wait time, toxicity management, and site capability. That is why CARVYKTI can be clinically superior in some settings and still be commercially constrained in others.
Johnson & Johnson itself is both partner and comparator. In Q1 2026 J&J reported CARVYKTI sales of $597 million worldwide, Tecvayli sales of $202 million, and Talvey sales of $152 million. That portfolio view matters more than a simple rival-product comparison. J&J can shape treatment habits across the myeloma continuum through Darzalex, CARVYKTI, Tecvayli and Talvey. For Legend, that is mostly an advantage because its partner has every reason to optimize CARVYKTI adoption when clinically appropriate. But it also means Legend is not the sole strategic mind behind the franchise. The product sits inside J&J’s broader myeloma chessboard.
The ecological niche is therefore clear. Legend is a leader in BCMA CAR-T economics exposure, a niche leader in commercial cell therapy as a standalone listed company, and still a challenger at the platform level because the rest of its pipeline remains early. If treatment shifts toward easier off-the-shelf regimens more quickly than expected, Legend’s niche weakens. If cell therapy continues to move earlier and manufacturing frictions keep easing, the niche strengthens because few competitors can match both long-term efficacy and global partner support.
Current fundamentals and valuation
Last four quarters and what the market is trading
Legend’s last four reported quarters show a company getting bigger fast and becoming cleaner more slowly. Q2 2025 collaboration revenue was $219.7 million, Q3 was $261.8 million, Q4 was $277.6 million, and Q1 2026 was $298.4 million. CARVYKTI net trade sales rose from about $439 million to $524 million to $555 million to $597 million over the same span. The trend is unmistakably positive. What is less straightforward is profit flow-through. Q1 2026 operating loss improved only slightly year over year to $(49.8) million because higher franchise gross profit was offset by capacity-expansion costs, depreciation and continuing commercialization spend.
Management’s late-2025 and early-2026 language was disciplined but ambitious. In November 2025 the company said it believed it could achieve CARVYKTI profitability by year-end 2025 and company-wide profitability in 2026. In March 2026 it said the CARVYKTI franchise had achieved profitability for full-year 2025. By May 2026 it was defining “company-wide profit” as adjusted net income rather than IFRS net income. That distinction is the correct one to watch. The franchise-profitability claim appears supported. The company-wide GAAP/IFRS-profitability claim remains unproven on the latest quarter.
The market is trading three things right now. First, it is trading the visible CARVYKTI ramp. Second, it is trading the margin path, especially whether Q1 2026’s cost spike was truly temporary. Third, after June 2026 it is trading LB2501 as a possible second-act story. That last factor matters more for the stock than for the model today. LB2501’s Phase 1 data were striking, but they were still 12 patients, with six treated at the higher dose level driving the sharpest efficacy headline. The right way to price that program today is as meaningful optionality, not as a near-term revenue line.
Valuation analysis
The accounting pass-through is good enough now that revenue multiples are more meaningful than they used to be, but not good enough that simple P/E is the right anchor. Over 2021–2025, net income did not convert into positive operating cash flow on a sustained basis; cumulative operating cash flow remained negative as the company built out commercialization and manufacturing. In that sense, owner earnings are still lower than the headline commercial story suggests. Investors should treat any valuation built on gross CARVYKTI trade sales as too generous, because the reported economics that accrue to Legend are lower and the cost-sharing mechanics are real.
Peer valuation is not especially helpful if used mechanically. Bristol Myers, Pfizer, Johnson & Johnson and Regeneron are diversified pharma companies, so they do not provide clean multiple anchors for a single-asset commercial biotech. The more useful comparison is economic position. CARVYKTI’s worldwide sales of $597 million in Q1 2026 were materially above Abecma’s 2025 quarterly run-rate and above sales for individual myeloma bispecifics such as Tecvayli and Talvey. That supports a premium to weaker or later-stage myeloma competitors. It does not justify valuing Legend as if it owned 100% of the franchise or as if platform diversification were already proven.
For absolute valuation, the most appropriate framework is a three-scenario commercial biotech model using attributable sales, margin development, and a revenue multiple that bakes in concentration risk. The assumptions below are deliberately conservative about how much of the current science premium should be capitalized into today’s stock. This is scenario analysis within a research framework, not investment advice.
| Dimension | Conservative | Base | Optimistic |
|---|---|---|---|
| Revenue and margin assumptions | CARVYKTI ramp slows; attributable revenue growth decelerates; company reaches only modest positive adjusted profitability | CARVYKTI continues broad earlier-line and ex-U.S. expansion; owner economics improve as one-time capacity costs fade | CARVYKTI keeps gaining earlier-line share; manufacturing friction eases faster; pipeline optionality receives partial market credit |
| Cash-flow assumptions | Cash burn narrows but free cash flow remains thin; further dilution remains possible | Cash conversion improves materially by 2027; no urgent financing need after June 2026 raise | Positive free cash generation emerges; balance sheet supports pipeline without near-term dilution |
| Multiple assumptions | ≈4.0x attributable forward sales | ≈4.8x attributable forward sales | ≈5.8x attributable forward sales plus modest platform premium |
| Key catalysts | Clean manufacturing execution; no negative safety surprise | Sustained quarterly sales growth, visible margin conversion, more community uptake | Additional earlier-line data, stronger ex-U.S. scale, repeatable LB2501/LB2102 validation |
| Key risks | Cost base stays high; demand is partly displaced by bispecifics | Margins improve slower than sales; single-asset concentration persists | Early-stage pipeline fails to reproduce initial promise; narrative premium fades |
| Implied value per ADS | about $30 | about $34–35 | about $48 |
| Implied upside from $29.91 | about 0%–2% | about 5%–8% | about 17%–20% |
| Permanent-loss risk | trigger: CARVYKTI ramp slows below manufacturing cost absorption needs | trigger: collaboration economics improve, but not enough to cover platform spend | trigger: valuation embeds platform success before proof, then compresses sharply |
The numbers tell a restrained story. The stock is no longer priced for fantasy. It is also not yet priced with a generous margin of safety. On this framework, the current price sits near the conservative fair value and modestly below the base value. That usually means the business is investable, but the stock is only selectively attractive. A patient investor would still prefer to buy closer to low-20s than around $30 because that is where the single-asset and governance risks are truly being paid for.
Risk analysis, catalysts and tracking indicators
Permanent-capital risks that matter
The first real risk is concentration. More than 90% of 2025 revenue came from collaboration revenue tied to CARVYKTI. If CARVYKTI growth slows materially, there is no second revenue stream ready to defend the P&L. Probability is medium; impact is high; the observable indicators are quarterly collaboration revenue growth, treatment-site expansion, ex-U.S. launch cadence, and cost-of-collaboration trends. The transmission path is direct: slower sales growth means weaker cost absorption, which means delayed profitability, which means either lower multiples or more dilution.
The second is manufacturing and operational scaling risk. Legend reported a 99% manufacturing success rate in Q1 2026 and more than 95% on-time order release, which is encouraging. But Q1 also showed how sensitive earnings are to capacity-expansion costs and depreciation. Probability is medium; impact is high; the indicators are turnaround time, gross margin on collaboration economics, inventory movement, and management commentary on Raritan, Belgium and Novartis-supported supply. If operational friction persists, the market will stop giving credit for headline sales growth because the profits will not follow.
The third is modality substitution. Abecma remains a direct CAR-T competitor, but the larger strategic threat comes from bispecifics and other easier-to-administer regimens that can move earlier in therapy. Pfizer highlighted positive Phase 3 Elrexfio data in patients with at least one prior line, J&J continues to build Tecvayli and Talvey, and Regeneron’s Lynozyfic is now approved in later-line settings. Probability is medium; impact is medium to high over 3–5 years; the indicators are label changes, NCCN or regional guideline placement, site-of-care migration, and physician adoption trends in community settings. The transmission path is lower patient share in the most attractive cohorts, which would cap the sales multiple even if CARVYKTI remains clinically strong.
The fourth is governance and geopolitical discount. The operating business is U.S.-centered and audited by a U.S.-inspected auditor, which reduces the most dramatic listing fears. But GenScript still has major ownership, related-party arrangements remain active, and U.S. congressional scrutiny of GenScript and its affiliates has not disappeared. Probability is medium; impact is medium unless legislation or enforcement escalates; the indicators are GenScript stake changes, board changes, related-party disclosure, and new U.S. government actions. The transmission path is mainly through multiple compression and investor base limitations rather than immediate revenue damage.
The fifth is dilution risk. The June 2026 offering proved management will issue stock when it thinks strategic flexibility is worth it. That can be rational capital allocation. It is still dilution. Probability is medium; impact is medium; the observable indicators are cash balances, lease and capex commitments, pipeline expansion pace, and any gap between adjusted profitability rhetoric and IFRS cash numbers. The transmission path is obvious: more shares outstanding reduce per-share value unless the proceeds create incremental returns above the cost of equity.
Catalysts, dashboard and key data tables
Positive catalysts over the next year are straightforward: continued quarterly CARVYKTI sales growth above market expectations; visible normalization of collaboration gross margins after Q1’s one-time costs; more ex-U.S. launch velocity; earlier-line clinical or label wins; and additional proof that LB2501 or LB2102 can evolve from curiosity to platform value. Negative catalysts are equally clear: manufacturing setbacks, another guidance reset on profitability timing, material safety-label deterioration, slower-than-expected center expansion, or another equity financing before company-wide profitability is established.
| Indicator | Latest / normal range | Alert threshold |
|---|---|---|
| CARVYKTI net trade sales growth | Q1 2026 was $597 million, +62% YoY | Two consecutive quarters below 20% YoY growth |
| Collaboration gross margin | Q1 2026 gross profit was $123.0 million on $298.4 million collaboration revenue | Margin below 35% for two quarters after one-time-cost period |
| Cash and time deposits | $834.6 million at 2026-03-31, before June 2026 raise | Falls below $600 million without clear self-funding path |
| Manufacturing success rate | 99% in Q1 2026 | Drops below 95% or turnaround time worsens materially |
| Global market footprint | 18 markets and 300+ sites by Q1 2026 | Site count stalls while demand remains strong |
| Related-party exposure | $14.3 million purchases from related parties in 2025 | Sharp increase without corresponding operational rationale |
| GenScript ownership | 47.2% as of 2026-02-28; estimated roughly 45% post-offering before any greenshoe exercise | Unexpected re-control moves or opaque stake changes |
| Next earnings report | Company had not yet posted a confirmed Q2 2026 date on IR as of 2026-07-03; external estimate clustered around 2026-08-10 and was explicitly unconfirmed | No company confirmation by late July 2026 |
The dashboard matters because Legend is now a company where operations tell the truth faster than narrative does. Sales show whether physicians still pull the product. Collaboration gross margin shows whether scale is paying off. Cash tells you whether the pipeline is being funded from the franchise or from shareholders. Manufacturing success and on-time delivery tell you whether the hardest part of the business is improving or merely being outgrown. The earnings-date item is a limitation: I could verify that the company had not yet posted a confirmed second-quarter 2026 earnings event on its IR pages, but the specific date remained externally estimated rather than company-confirmed.
| Key figures | Total revenue | Collaboration revenue | Net loss | Operating cash flow |
|---|---|---|---|---|
| 2020 | 75.0 | — | n.a. in this table set | (223.0) |
| 2021 | 68.8 | — | (403.6) | (198.5) |
| 2022 | 117.0 | 66.7 | (446.3) | (201.3) |
| 2023 | 285.1 | 249.8 | (518.3) | (393.3) |
| 2024 | 627.3 | 482.6 | (177.0) | (144.0) |
| 2025 | 1,028.9 | 944.8 | (296.8) | (100.2) |
The long arc is favorable even with the ugly 2023 cash outflow. Revenue has scaled dramatically, collaboration revenue has become dominant, and operating cash burn has narrowed again after the buildout shock. But the table also shows why the stock still deserves valuation discipline. This is not yet a mature cash compounder.
Cross-synthesis summary
Legend’s real achievement, looking across the whole journey, is that it has already done one hard thing that many biotech companies never do. It took a partnered cell-therapy program from development into a global commercial franchise and kept the product clinically differentiated while scaling manufacturing across multiple sites and geographies. That is not luck. It reflects technical competence, partner selection, and a willingness to build operational muscle instead of outsourcing the hard parts of commercialization. The company has proven it can create, transfer and scale value in one exceptionally difficult modality.
What made that success possible was not one factor. The clinical advantage of cilta-cel mattered first. Johnson & Johnson’s commercial machine mattered second. Manufacturing investment mattered third. The current question is how many of those success factors still compound from here. The therapy franchise clearly still does. The partner support clearly still does. Manufacturing is improving, but it is also the main place where success can turn into self-inflicted friction if too much capacity is added faster than margin can absorb it. Platform optionality exists, but it is early. That matters because today’s valuation already gives Legend more credit than a plain single-franchise runoff would deserve, though much less credit than a fully diversified oncology platform would command.
The market’s most likely misjudgment right now is on timing, not direction. It probably underestimates how durable CARVYKTI’s franchise can be if manufacturing execution stays on track, ex-U.S. access keeps broadening, and earlier-line penetration continues. At the same time, it likely overestimates how quickly that durability becomes clean, broad, self-funded corporate profitability. The June 2026 capital raise is the clearest single fact behind that caution. I think the stock now reflects a sensible respect for the asset and an incomplete respect for the remaining execution risk. That is why the right stance is neither aggressively bullish nor dismissive. It is selective.
Bull and bear reasons
Bull reasons:
- CARVYKTI remains one of the strongest efficacy stories in relapsed or refractory myeloma, with five-year CARTITUDE-1 data showing median overall survival of 60.7 months and about one-third of patients progression-free for at least five years.
- Commercial momentum is still strong: CARVYKTI net trade sales climbed to about $597 million in Q1 2026, up 62% year over year, with ex-U.S. growth far outpacing U.S. growth.
- Manufacturing metrics improved materially in Q1 2026, including a reported 99% manufacturing success rate and over 95% on-time release, which directly addresses the main bottleneck in autologous CAR-T scale.
- The company has meaningful platform optionality after early LB2501 and LB2102 data, especially LB2501’s proof-of-concept in in vivo CAR-T, which is the first real sign that Legend may become more than a one-franchise story.
Bear reasons:
- Revenue concentration is extreme: in 2025, collaboration revenue tied mainly to CARVYKTI accounted for the overwhelming majority of total revenue, so a single franchise slowdown would hit the whole equity story.
- Legend does not own the full CARVYKTI economics outside Greater China; it shares costs and profits 50/50 with Janssen, which caps the portion of franchise upside that reaches Legend shareholders.
- Q1 2026 showed that higher CARVYKTI sales do not automatically translate into reported profitability because manufacturing expansion and depreciation can absorb the incremental gross profit.
- The June 2026 ADS offering showed that dilution risk remains live even after major franchise ramp, which weakens the self-funding argument and raises the hurdle for per-share compounding.
- Governance and geopolitical discount remain justified by GenScript’s large stake, related-party transactions, a non-independent chair, and recurring U.S. congressional scrutiny of the wider GenScript group.
Pre-mortem
The most likely script for a 50% drawdown over the next three years is commercial deceleration plus multiple compression, not clinical failure. One plausible path is that bispecific competition moves earlier faster than expected in 2027, treatment centers reserve CAR-T for narrower patient subsets, CARVYKTI growth slows toward the teens, collaboration margin fails to expand because manufacturing and market-access costs remain high, and the market cuts Legend from a roughly growth-biotech sales multiple to a more ordinary single-franchise multiple. If attributable revenue expectations stall around $1.1–1.2 billion and the multiple compresses from roughly 4.5x to 5.0x sales down toward 2.5x to 3.0x, the stock could plausibly fall into the mid-teens.
A second plausible script is operational rather than competitive. Manufacturing metrics look strong in Q1 2026, but if capacity additions produce recurring excess cost, delivery slips, or another meaningful safety-label burden, growth could stay respectable while earnings quality worsens. Add a second dilutive capital raise to that script, and the stock could re-rate from “commercial ramp with platform option” to “perpetual spender with one good product.” That kind of narrative reset often halves biotech stocks even without a collapse in top-line sales.
Final research conclusion
Legend is worth owning only with a clear understanding of what you own. You do not own a diversified oncology platform yet. You own a high-quality share of one globally important myeloma franchise, a good but not perfect operating build-out around that franchise, and an early claim on a next-generation cell-therapy platform whose most exciting assets are still far from de-risked. The company’s success to date is real. The stock’s burden of proof is now about conversion: from sales into profits, from franchise into company, and from science option into repeatable platform value.
At $29.91, I do not think the shares are overpriced in any dramatic sense. I also do not think they offer a wide margin of safety for a new buyer. The franchise is too good for “Avoid,” but the concentration, dilution, and governance risks are too real for a straight “Buy” at the current level. The right stance is to respect the business and demand more price discipline than the story alone encourages. I would become more constructive if further quarters show that Q1 2026’s cost pressure was genuinely transitory and that company-wide profitability is arriving without another financing event. I would become less constructive if CARVYKTI growth stays strong but margin conversion keeps slipping, because that would mean the business is scaling operational complexity faster than shareholder value.
【Company-profile scores】
- Fundamental quality: medium
- Growth: high
- Moat: medium
- Financial soundness: medium
- Management credibility: medium
- Valuation attractiveness: medium
- Risk level: high
- Suitable investor type: long-term growth
【Investment rating】
- Rating: Hold
- One-line thesis: CARVYKTI is a real franchise, but the current price still does not pay generously for single-asset concentration, shared economics, and continuing dilution risk.
- 【Ideal Buy Price】22–24 USD Basis: at least a 20% margin of safety below the conservative scenario value of about $30 per ADS.
- Acceptable hold price: 29–39 USD
- Clearly overvalued price: 53 USD and above
- Current-price classification: acceptable hold
- Whether to wait for a better price: yes. New capital looks more attractive below $24, or above the current price only if Legend proves two further quarters of clean margin conversion and no renewed financing need. The opportunity cost of waiting is missing further CARVYKTI upside if profitability inflects faster than expected.
- Target holding horizon: 3–5 years
- Expected annualized return: conservative 0%–2%; base 5%–8%; optimistic 17%–20%
- Max-loss risk: roughly 45%–55% in a combined script of slower CARVYKTI growth, persistent cost pressure, and multiple compression toward a single-franchise biotech valuation
- Reassessment-trigger signals: collaboration gross margin below 35% for two consecutive quarters after Q1 2026’s one-time-cost period; CARVYKTI sales growth below 20% YoY for two consecutive quarters; another dilutive equity issuance before company-wide profitability is visible; a material worsening in safety-label burden; clear evidence that bispecific adoption is displacing CARVYKTI in earlier-line settings faster than management planned.
【Valuation Range】
- current: 29.91 (close as of 2026-07-02)
- bear (conservative · ideal buy zone): [22, 24]
- base (fair · acceptable hold zone): [29, 39]
- bull (optimistic · above the clearly-overvalued line): [53, 58]
Open questions and limitations
I could directly verify the current U.S. label, the EU earlier-line context, and Japan’s original later-line approval pathway, but I did not independently capture a current regulator-source wording for every regional label, especially China, in time for this report. I also verified that the company had not posted a confirmed Q2 2026 earnings event on its IR pages, but the specific next-report date remained externally estimated rather than company-confirmed. Finally, my post-offering GenScript stake is a mathematical estimate from disclosed holdings and disclosed post-offering shares outstanding, not a separately filed updated beneficial-ownership statement.
Sources and other tickers mentioned
Sources
Primary sources used most heavily in this report were Legend Biotech’s 2025 Form 20-F, Legend’s Q3 2025, Q4 2025 and Q1 2026 earnings releases, the company’s historic price lookup page, the June 2026 prospectus supplement, FDA and EMA label materials, Johnson & Johnson’s Q1 2026 release, Pfizer’s Q1 2026 release, Bristol Myers Squibb’s Q4 and FY 2025 release, and official government materials and Reuters reporting on GenScript-related U.S. scrutiny.
Other tickers mentioned
- JNJ.US: global CARVYKTI partner and owner of key myeloma comparator assets including Tecvayli and Talvey.
- BMY.US: owner of Abecma, the closest direct BCMA CAR-T competitor.
- PFE.US: owner of Elrexfio, a BCMA bispecific that can affect treatment sequencing.
- REGN.US: owner of Lynozyfic, another BCMA bispecific adding later-line competition.
- 1548.HK: GenScript, Legend’s founding major shareholder and governance overhang.
- EXEL.US: referenced through board biography context for Tomas Heyman.
- AKRO.US: referenced through board biography context for Tomas Heyman.
This report is based on public information and does not constitute investment advice. Markets carry risk; invest with caution.
Full report
Sign in to read the full report
Sign up free to unlock the full text, the Baillie growth scorecard, and full-text search.
Log in / Sign up free